Short- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19

BACKGROUND: After its introduction as standard-of-care for severe COVID-19, dexamethasone has been administered to a large number of patients globally. Detailed knowledge of its impact on the cellular and humoral immune response to SARS-CoV-2 remains scarce. METHODS: We included immunocompetent indi...

Descripción completa

Detalles Bibliográficos
Autores principales: Thibeault, Charlotte, Bardtke, Lara, Vanshylla, Kanika, di Cristanziano, Veronica, Eberhardt, Kirsten A., Stubbemann, Paula, Hillus, David, Tober-Lau, Pinkus, Mukherjee, Parnika, Münn, Friederike, Lippert, Lena J., Helbig, Elisa T., Lingscheid, Tilman, Steinbeis, Fridolin, Mittermaier, Mirja, Witzenrath, Martin, Zoller, Thomas, Klein, Florian, Sander, Leif E., Kurth, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243822/
https://www.ncbi.nlm.nih.gov/pubmed/36881474
http://dx.doi.org/10.1172/jci.insight.166711

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243822/
https://www.ncbi.nlm.nih.gov/pubmed/36881474
http://dx.doi.org/10.1172/jci.insight.166711

Ejemplares similares